Glow LifeTech (GLOW) AI Stock Analysis

• Market Cap: C$8.54M
• Dividend Yield: N/A
• Average Volume (3M): 266.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 327.55%
• EPS Growth: 21.37%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 170,729,600
• 10 Day Avg. Volume: 165,602
• 30 Day Avg. Volume: 266,047
• PEG Ratio: -0.30
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 7.42
• P/FCF Ratio: -4.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Glow LifeTech's overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates a bearish trend, and valuation metrics reflect ongoing losses. The absence of earnings call data and corporate events means these factors do not influence the score.

Glow LifeTech Business Overview & Revenue Model

Company Description

Glow Lifetech Corp., a biotechnology company, focuses on producing nutraceutical and cannabinoid-based products in North America. The company engages in the commercialization of two technologies, such as MyCell Enhanced technology, a nutraceutical and cannabis nutrient delivery technology; and a cannabis Smart Consumption System to assist users and patients to store, journal, control, consume, and manage cannabis related products. The company has the exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K, and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company was incorporated in 2018 and is based in Toronto, Canada.

How the Company Makes Money

Glow LifeTech generates revenue through multiple streams, primarily from the sale of its health supplements and skincare products through both online and offline retail channels. The company operates a direct-to-consumer e-commerce platform, which allows it to capture higher margins by selling directly to customers. Additionally, GLOW has established partnerships with various health and wellness retailers, providing its products in physical stores and expanding its market reach. The company also engages in subscription-based models for certain product lines, ensuring consistent revenue flow. Furthermore, GLOW invests in research and development to innovate new products, which can lead to increased sales and market share, thereby enhancing its financial performance.

Glow LifeTech Financial Statement Overview

Summary

Glow LifeTech is experiencing strong revenue growth, but profitability remains elusive with significant net losses. The balance sheet shows a low debt burden, but the company struggles with negative equity returns. Cash flow challenges persist, indicating a need for improved operational efficiency and cost management to achieve sustainable profitability.

Income Statement

Glow LifeTech has shown significant revenue growth of 51.4% in the latest year, which is a positive indicator. However, the company is still operating at a loss with a negative net profit margin of -317.75% and negative EBIT and EBITDA margins. The high gross profit margin of 70.68% suggests potential for profitability if operational efficiencies improve.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.16, indicating manageable debt levels. However, the negative return on equity of -103.37% highlights significant losses relative to shareholder equity. The equity ratio of 69.06% suggests a strong equity base compared to total assets, but overall financial health is weakened by persistent losses.

Cash Flow

Glow LifeTech's cash flow situation remains challenging with negative operating cash flow and free cash flow. The free cash flow to net income ratio is slightly positive at 1.01, indicating that free cash flow covers net income losses. However, the negative operating cash flow to net income ratio reflects ongoing cash burn issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.45M	836.19K	43.93K	0.00	0.00	0.00
Gross Profit	696.10K	591.00K	-759.18K	-263.26K	-43.39K	0.00
EBITDA	-1.28M	-1.24M	-1.31M	-1.92M	-4.59M	-153.00K
Net Income	-2.62M	-2.66M	-1.59M	-2.24M	-11.31M	-153.00K
Balance Sheet
Total Assets	3.69M	3.72M	1.91M	2.31M	3.76M	2.60K
Cash, Cash Equivalents and Short-Term Investments	1.06M	1.29M	34.00	75.19K	746.02K	1.80K
Total Debt	486.27K	404.08K	171.75K	147.36K	39.93K	6.40K
Total Liabilities	1.42M	1.15M	2.35M	1.14M	328.03K	315.57K
Stockholders Equity	2.26M	2.57M	-433.12K	1.16M	3.44M	-312.97K
Cash Flow
Free Cash Flow	-1.10M	-1.36M	-490.86K	-1.36M	-3.62M	-18.65K
Operating Cash Flow	-1.06M	-1.35M	-417.26K	-1.30M	-3.18M	-18.65K
Investing Cash Flow	-31.79K	16.70K	-60.91K	18.31K	-541.41K	-1.36K
Financing Cash Flow	1.79M	2.62M	445.01K	491.44K	4.59M	2.93K

Glow LifeTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLOW, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLOW.

Glow LifeTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$15.41M	―	-175.45%	―	-3.93%	-575.24%
GLOW	42 Neutral	C$8.54M	―	-250.28%	―	327.55%	21.37%
KNE	42 Neutral	C$6.65M	―	-813.02%	―	―	―
BIOV	29 Underperform	$7.29M	―	―	―	―	25.09%
BETR	21 Underperform	$9.87M	―	26.73%	―	―	85.61%

Glow LifeTech Corporate Events

Glow LifeTech Strengthens Board with New Appointment

Glow LifeTech Corp. has appointed David Côté, a seasoned leader in the cannabis retail industry, to its Board of Directors. Côté’s experience in scaling retail operations is expected to aid Glow’s expansion in the Canadian cannabis retail market, aligning with the company’s growth strategy. The appointment is accompanied by a grant of stock options, and coincides with internal changes where James Van Staveren steps down from the Audit Committee and Corporate Secretary roles, with Côté and CFO Josh Bald taking over those positions, respectively.

Glow LifeTech Expands MOD™ Drops to New Brunswick, Entering Atlantic Canada

Glow LifeTech has announced its expansion into the New Brunswick market with its MOD™ drops, marking its first entry into Atlantic Canada. This strategic move follows a successful year in Ontario and aligns with the company’s growth strategy to broaden its footprint across Canada, leveraging its proprietary technology to capture new market opportunities and drive growth.

Glow Lifetech Issues Stock Options to Team

Glow Lifetech Corp has granted 3,650,000 stock options to its officers and consultants, offering an opportunity for increased insider participation. The options come with a five-year exercise period, highlighting the company’s commitment to incentivizing its team amid its innovative focus on nutraceutical and cannabinoid-based products.

Glow Lifetech Finalizes Share Issuance and Debt Settlement

Glow Lifetech Corp. plans to issue 10 million shares to finalize its acquisition of Swiss Pharma, strengthening their strategic partnership in the cannabis and natural health sectors. Additionally, Glow intends to settle $510,470.44 in outstanding debt by issuing over 8 million shares, aiming to preserve cash for working capital.

Glow LifeTech Reports Strong Q3 2024 Results

Glow LifeTech Corp. reported a strong Q3 2024 with a 49% increase in revenue and 73% gross margins, reflecting its commitment to profitability and growth. The company improved its financial health through significant financing and debt settlement, enabling strategic investments. Glow also expanded its retail footprint in Ontario, positioning itself as a leader in the oils category.

Glow Lifetech Completes Funding and Debt Settlement

Glow Lifetech Corp. successfully completed a $900,000 private placement and settled $591,000 in debt by issuing shares, aimed at preserving cash for working capital. Insiders participated in the transaction, which was classified as a related party transaction, and Nova Capital Corp. increased its stake in the company. This strategic move reflects Glow Lifetech’s efforts to strengthen its financial standing.